Collegium Pharmaceutical(COLL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Collegium Reports First Quarter 2024 Financial Results – Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca® Revenue of$50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income of $27.7 Million vs. Q1'23 GAAP Net Loss of$(17.4) Million – – Delivered Q1'24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Reaf irmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 9, ...